Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).

NCT07234695 is registered in ClinicalTrials.gov with Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau as lead sponsor.

NCT NCT07234695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07234695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).
Lead sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase
Phase 3
Overall status
Recruiting
Start date
December 22, 2025
Completion date
July 31, 2028
Enrollment
120 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer blood biomarkers, alzheimer dementia, alzheimer dementia (ad), alzheimer disease, alzheimer disease (ad), down syndrome, down syndrome (ds), down syndrome (trisomy 21), epilepsy, seizures